Update: NCCN prostate cancer clinical practice guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue SUPPL. 1, 2005, Pages

  Scardino, Peter ^a,b  

^a Memorial Sloan Kettering Cancer Center ^*

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Digital rectal examination; NCCN Clinical Practice Guidelines; Prostate cancer; Prostate specific antigen; Prostatectomy

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; FINASTERIDE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; HORMONAL THERAPY; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; AGED; ARTICLE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE TUMOR; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TAXOIDS; UNITED STATES;

EID: 33644842511     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003;289:2695-700.
2. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Eng J Med 2003;349:215-49.
3. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350: 2239-2246.
4. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized cancer. A multi-institutional update. JAMA 1997;277:1445-1451.
5. Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2004;171(Pt 1):2255-2259.
6. Albertsen PC, Namley JA, Gleason DF, Marry MJ. Competing risk analysis of men aged 55 to 74 at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-980.
7. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347: 781-789.
8. Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004;171: 1520-1524.
9. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291: 2713-2719.
10. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
11. Eisenberger MA, De Wit R, Berry W, et al. A multicenter phase III comparison of docetaxel (D) + predisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 2004; 22[suppl]:4.
12. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004:351:1502-1512.
13. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.